



Takeru Funakoshi

M.D., Ph.D.

Current Appointments

Associate Professor, Department of Dermatology

Keio University School of Medicine

Education and Training

1995-2001	Keio University School of Medicine
2001-2003	Department of Dermatology Keio University, Graduate School of Medicine
2003-2004	Resident, Department of General Medicine, Kawasaki Municipal Hospital, Kanagawa
2004-2006	Instructor, Department of Dermatology, Teikyo University Chiba Medical center, Chiba
2006-2009	Instructor, Department of Dermatology, Keio University School of Medicine, Tokyo

Expertise

- Pemphigus, extramammary Paget's disease, malignant melanoma

Fellowship Appointments

2009-2010	Visiting scholar, Department of Dermatology, University of Pennsylvania, Philadelphia, USA
-----------	---

Faculty Appointments

2010-2021	Ward Manager, Department of Dermatology, Keio University Hospital
-----------	---

2022-present Associate Professor, Department of Dermatology, Keio University Hospital

Awards and Honors

- 2007 An Award for an Outstanding Oral Presentation in The 34th Annual Meeting of the Society for Cutaneous Ultrastructure Research, Prague.
- 2010 Albert Kligman Travel Fellowship Award in The 2010 Society of Investigative Dermatology Annual Meeting, Atlanta

Medical Societies

- Japanese Dermatological Association (Member, 2001-present)
- The Japanese Society of Internal Medicine (Member, 2003-present)
- Society for Skin Structure Research (Member, 2006-present)
- Japanese Skin Cancer Society (Member, 2008-present)
- Japanese Board of Cancer therapy (Member, 2012-present)
- Japan Research Association for Immunotherapies (Member, 2017-present)
- Japanese Society for Investigative Dermatology (Member, 2018-present)

Selected Publications

(over 90 publications; total citation 917; h-index 15; ORCID 0000-0002-8893-4590)

1. Funakoshi T, Lunardon L, Ellebrecht CT, Nagler AR, O'Leary CE, Payne AS. Enrichment of total serum IgG4 in patients with pemphigus.
Br J Dermatol 167(6):1245-53, 2012
Pubmed: <https://pubmed.ncbi.nlm.nih.gov/22803659/>
2. Fukuda K, Sugihara E, Ohta S, Izuhara K, Funakoshi T, Amagai M, Saya H. Periostin Is a Key Niche Component for Wound Metastasis of Melanoma.
PLoS One. 10(6):e0129704, 2015
Pubmed: <https://pubmed.ncbi.nlm.nih.gov/26083413/>
3. Nakamura Y, Kitano S, Takahashi A, Tsutsumida A, Namikawa K, Tanese K, Abe T, Funakoshi T, Yamamoto N, Amagai M, Yamazaki N. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.
Oncotarget. 7(47):77404-77415, 2016

Pubmed: <https://pubmed.ncbi.nlm.nih.gov/27764805/>

4. Fukuda K, Funakoshi T, Sakurai T, Nakamura Y, Mori M, Tanese K, Tanikawa A, Taguchi J, Fujita T, Okamoto M, Amagai M, Kawakami Y. Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.
Melanoma Research. 27(4):326-334, 2017
Pubmed: <https://pubmed.ncbi.nlm.nih.gov/28263240/>
5. Hirai I, Tanese K, Nakamura Y, Otsuka A, Fujisawa Y, Yamamoto Y, Hata H, Fujimura T, Matsushita S, Yoshino K, Kameyama K, Amagai M, Funakoshi T. Assessment of the methods used to detect HER2-positive advanced extramammary Paget's disease.
Medical Oncology. 35(6):92, 2018
Pubmed: <https://pubmed.ncbi.nlm.nih.gov/29744813/>
6. Nakamura Y, Tanese K, Hirai I, Amagai M, Kawakami Y, Funakoshi T. Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget's disease.
Br J Dermatol 181(3):535-543, 2019
Pubmed: <https://pubmed.ncbi.nlm.nih.gov/30791097/>
7. Fusumae T, Fukuda K, Hirai I, Nakamura Y, Tanese K, Iwata T, Funakoshi T. Outcomes in Extramammary Paget's Disease Patients With Brain Metastasis: A Retrospective Analysis.
J Am Acad Dermatol. 83(6):1832-1834, 2020
Pubmed: <https://pubmed.ncbi.nlm.nih.gov/32450098/>
8. Hirai I, Funakoshi T, Kamijuku H, Fukuda K, Mori M, Sakurai M, Koda Y, Kato J, Mori T, Watanabe N, Noji S, Yaguchi T, Iwata T, Ohta S, Fujita T, Tanosaki R, Handa M, Okamoto S, Amagai M, Kawakami Y. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
Cancer Science. 112(8):3163-3172, 2021
Pubmed: <https://pubmed.ncbi.nlm.nih.gov/34101300/>
9. Fukuda K, Okamura K, Riding RL, Fan X, Afshari K, Haddadi NS, McCauley SM, Guney MH, Luban J, Funakoshi T, Yaguchi T, Kawakami Y, Khvorova A, Fitzgerald KA, Harris JE. AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma.
Journal of Experimental Medicine. 2021;218(9):e20200962. doi: 10.1084/jem.20200962.
Pubmed: <https://pubmed.ncbi.nlm.nih.gov/34325468/>